The system previously received regulatory approval for use in the lumbar region of the spine. Credit: JAFAR AHMED / Unsplash.

Milestone Scientific has received 510(k) clearance from the US Food and Drug Administration (FDA) for its CompuFlo Epidural System to be used in the thoracic region of the spine, including the cervical thoracic junction.

The CompuFlo Epidural System previously received regulatory approval for use within the lumbar region of the spine, focusing on labour and delivery.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The system will use the company’s patented DPS Dynamic Pressure Sensing Technology in the newly expanded indications.

This will help anaesthesiologists and pain management providers easily navigate the challenging anatomy of the thoracic region and cervical thoracic junction in real time.

It will also simplify the epidural procedure by confirming the needle placement both audibly and visually.

Based on published clinical data, the CompuFlo Epidural System offers clinical and safety benefits that include significantly reduced complication rates and dural puncture numbers.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Furthermore, in an independent study, the system was found to reduce costs related to morbidity, offering healthcare institutions a direct economic benefit.

Milestone Scientific CEO Arjan Haverhals said: “Given the extensive published clinical data supporting successful epidural placement, we are pleased to expand the scope of indications beyond labour and delivery into challenging thoracic and cervical epidural procedures, where the incidence rates of morbidity are believed to be much higher, at 17% and 30%, respectively.

“The FDA clearance represents a major milestone as it broadens the market opportunity for CompuFlo Epidural System, with approximately 11 million epidural procedures performed in the US on an annual basis.”

The company intends to expand the use of its technology within the area of pain management.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact